SCHEMBL22711544

SCHEMBL22711544

Cc1ncc(OCC(=O)O)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.52
NR4A1 P22736 1/20 0.47
APEX1 P27695 1/20 0.47
MCL1 Q07820 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HPGD P15428 1/20 0.46
PTPRB P23467 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 1/20 0.46
ALDH1A1 P00352 3/20 0.44
TSHR P16473 1/20 0.43
FFAR1 O14842 3/20 0.43
PTPN7 P35236 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 1/20 0.42
PTPN12 Q05209 1/20 0.42
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22723792 0.82 MEN1 (0.42) SMN1; SMN2HPGDHSD17B10LMNAALDH1A1
SCHEMBL22396772 0.80 LMNA (0.51) ALOX15NR4A1APEX1MCL1SMN1; SMN2
SCHEMBL23321188 0.79 ALOX15 (0.52) ALOX15MCL1SMN1; SMN2LMNAALDH1A1
SCHEMBL13965559 0.79 L3MBTL1 (0.49) MCL1TSHRFFAR1
SCHEMBL2435587 0.79 ALOX15 (0.52) ALOX15NR4A1APEX1MCL1SMN1; SMN2
SCHEMBL29416383 0.79 ALOX15 (0.52) ALOX15NR4A1APEX1MCL1SMN1; SMN2
Bromide SCHEMBL6993690 0.77 SMN1; SMN2 (0.50) ALOX15NR4A1APEX1MCL1SMN1; SMN2
SCHEMBL7446499 0.77 ALOX15 (0.54) ALOX15NR4A1APEX1MCL1SMN1; SMN2
SCHEMBL25171222 0.76 ALOX15 (0.48) ALOX15NR4A1APEX1MCL1SMN1; SMN2
SCHEMBL22990885 0.76 PTPN1 (0.41) HPGDHSD17B10LMNAALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3744721-B1 CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT SHIONOGI & CO (JP) 2025-07-02 EP disclosed
CN-111801330-B Fused ring compounds having dopamine D3 receptor antagonism 盐野义制药株式会社 2024-04-05 CN disclosed
US-11578084-B2 Condensed ring compounds having dopamine D3 receptor antagonistic effect SHIONOGI & CO., LTD. (JP) 2023-02-14 US disclosed
US-20210047315-A1 CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT SHIONOGI & CO., LTD. (JP) 2021-02-18 US disclosed
US-20210040117-A1 CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT SHIONOGI & CO., LTD. (JP) 2021-02-11 US disclosed
EP-3744721-A1 CONDENSED CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISM Shionogi & Co., Ltd (JP) 2020-12-02 EP disclosed
CN-111801330-A Fused ring compounds having dopamine D3 receptor antagonism 盐野义制药株式会社 2020-10-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210047315-A1 CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT DRD3, DRD2, DRD1 ALOX15 3645/4885NR4A1 127/4885APEX1 4119/4885
US-20210040117-A1 CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT DRD3, DRD2, DRD1 ALOX15 4042/4885NR4A1 238/4885APEX1 4152/4885
US-11578084-B2 Condensed ring compounds having dopamine D3 receptor antagonistic effect DRD3, DRD2, DRD1 ALOX15 4042/4885NR4A1 238/4885APEX1 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.